US pricing erosion may resume
While pricing has stabilized recently, any reversal could pressure US margins and revenue growth.
medium · analyst_question
Aurobindo Pharma Limited — Q1 FY24
Aurobindo Pharma delivered a robust Q1 FY24 with revenue of INR 6,850 crore (+9.9% YoY) and EBITDA of INR 1,151 crore (+19.3% YoY), driven by strong US formulation growth (+11.2...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Revlimid launch volume uncertainty
As a late entrant, Aurobindo's Revlimid volume share is expected to be lower than early entrants, limiting upside.
medium · management_commentaryPLI Pen-G ramp-up delays
Management acknowledged that full ramp-up of Pen-G capacity may take time, with clarity only expected by February 2024.
medium · management_commentaryBiosimilar revenue visibility low
Management declined to provide revenue projections for biosimilars, citing evolving market dynamics, indicating high uncertainty.
low · analyst_question